Wilhelm Kaci, Yang Daisy
University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 377, Houston, Texas 77030, USA.
J Oncol Pharm Pract. 2011 Jun;17(2):91-103. doi: 10.1177/1078155209354931. Epub 2010 Jan 19.
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and has a heterogeneous clinical course. Some patients experience an indolent disease course, which does not require treatment or affect their overall quality of life. Other patients present with symptomatic advanced disease that rapidly progresses and requires therapy. For these patients, chemotherapy is the mainstay of treatment and has undergone significant evolution in the past few decades. From alkylating agents to purine analogs, response rates have greatly improved with new chemotherapy regimens. The development of chemoimmunotherapy regimens has also transformed the treatment of CLL. This article will review front-line treatment options for CLL and discuss the updated National Comprehensive Cancer Network guidelines.
慢性淋巴细胞白血病（CLL）是最常见的成人白血病，其临床病程具有异质性。一些患者经历惰性病程，无需治疗或不影响其总体生活质量。其他患者则表现为有症状的晚期疾病，疾病迅速进展且需要治疗。对于这些患者，化疗是主要的治疗方法，在过去几十年中经历了重大演变。从烷化剂到嘌呤类似物，新的化疗方案使缓解率有了很大提高。化疗免疫治疗方案的发展也改变了CLL的治疗方式。本文将回顾CLL的一线治疗选择，并讨论更新后的美国国立综合癌症网络指南。
